ZenaTech Reports Annualized Revenue Run Rate of Approximately CAD $33 Million Based on First Quarter 2026 Revenue

ZenaTech annualized its Q1 2026 revenue run rate to ~CAD $33 million (CAD $8.3 million in Q1, annualized x4), attributing the scale to its DaaS model and partial-year acquisition contributions integrating over the past year. Management said the CAD $33 million is a baseline rather than guidance, with several acquisitions expected to contribute full 12-month revenue later in fiscal 2026. The firm also outlined a May 2026 Partnership Acquisition Program via non-binding LOIs/term sheets to pursue founder-led, profitable targets across defense/unmanned systems, enterprise SaaS, AI infrastructure/applied AI, and specialty manufacturing/supply chain.

Analysis

The signal here is less about revenue level and more about proof that ZENA’s roll-up can manufacture a repeatable acquisition-to-integration flywheel. Near term, that tends to support the stock because microcap investors pay up for visible top-line acceleration, but the economic quality matters more than the headline rate: acquisition-led growth usually improves reported revenue faster than per-share value unless the business can show same-store uplift, gross margin expansion, and restrained dilution.

The real second-order risk is that the strategy becomes capital-markets dependent. If the market stops rewarding every acquisition with a higher multiple, future deals will likely come at lower accretion and higher equity issuance, which can trap the stock in a dilution loop even if revenue keeps rising. The key falsifier over the next 1-3 months is whether Q2/Q3 delivers organic growth, margin lift, and stable share count; if not, this is just a balance-sheet-funded revenue roll-up with limited earnings power. No meaningful read-through to TGT; QUBT is only a loose thematic cousin and should not be treated as a beneficiary absent actual quantum revenue or product traction.

Key Decisions for Investors

• Avoid chasing ZENA after the print; treat it as a watchlist name until the next quarterly filing confirms organic growth and share-count discipline. Upside exists, but the burden of proof is on margins and cash conversion, not revenue run rate.
• If forced to trade it, use a small tactical long in ZENA only on a pullback of 10-15% from post-release levels, with a hard stop if the next update shows dilution or no sequential margin improvement.
• Watch for a financing event or share issuance over the next 1-3 months; that is the highest-probability negative catalyst and would invalidate the bullish roll-up narrative.
• No actionable trade in QUBT or TGT from this release; do not confuse ZENA’s acquisition-led microcap execution story with a broad quantum or retail read-through.